FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension
Status: Currently in Shortage
»Date first posted: 01/22/2018
»Therapeutic Categories: Pediatric; Psychiatry

Expand all

Pfizer Pharmaceuticals (Reverified 06/14/2018)

Company Contact Information:
800-533-4535

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Bottles of 300 mg powder (to prepare 60 mL suspension)(NDC 24478-190-10) Next Delivery and Estimated Recovery: TBD Shortage per Manufacturer: Manufacturing Delay

Dear Health Care Provider Letter

Other
Bottles of 600 mg powder (to prepare 120 mL suspension)(NDC 24478-200-20) Limited Supply Available Check Wholesaler for Availability

Dear Health Care Provider Letter

Other
Bottles of 750 mg powder (to prepare 150 mL suspension)(NDC 24478-205-25) Limited Supply Available Check Wholesaler for Availability

Dear Health Care Provider Letter

Other
Bottles of 900 mg powder (to prepare 180 mL suspension)(NDC 24478-210-30) Limited Supply Available Check Wholesaler for Availability

Dear Health Care Provider Letter

Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English